Cargando…
The Fibronectin–ILT3 Interaction Functions as a Stromal Checkpoint that Suppresses Myeloid Cells
Suppressive myeloid cells inhibit antitumor immunity by preventing T-cell responses. Immunoglobulin-like transcript 3 (ILT3; also known as LILRB4) is highly expressed on tumor-associated myeloid cells and promotes their suppressive phenotype. However, the ligand that engages ILT3 within the tumor mi...
Autores principales: | Paavola, Kevin J., Roda, Julie M., Lin, Vicky Y., Chen, Peirong, O'Hollaren, Kyle P., Ventura, Richard, Crawley, Suzanne C., Li, Betty, Chen, Hung-I H., Malmersjö, Seth, Sharkov, Nikolai A., Horner, Geoffrey, Guo, Wei, Kutach, Alan K., Mondal, Kalyani, Zhang, Zhen, Lichtman, Joshua S., Song, Christina, Rivera, Lee B., Liu, Wenhui, Luo, Jian, Wang, Yan, Solloway, Mark J., Allan, Bernard B., Kekatpure, Avantika, Starck, Shelley R., Haldankar, Raj, Fan, Bin, Chu, Chun, Tang, Jie, Molgora, Martina, Colonna, Marco, Kaplan, Daniel D., Hsu, Jer-Yuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414285/ https://www.ncbi.nlm.nih.gov/pubmed/34426457 http://dx.doi.org/10.1158/2326-6066.CIR-21-0240 |
Ejemplares similares
-
Expression of immunoglobulin-like transcript (ILT)2 and ILT3 in human gastric cancer and its clinical significance
por: ZHANG, YI, et al.
Publicado: (2012) -
A Novel Inhibitory Receptor (ILT3) Expressed on Monocytes, Macrophages, and Dendritic Cells Involved in Antigen Processing
por: Cella, Marina, et al.
Publicado: (1997) -
Soluble HLA-G and HLA-G Bearing Extracellular Vesicles Affect ILT-2 Positive and ILT-2 Negative CD8 T Cells Complementary
por: Schwich, Esther, et al.
Publicado: (2020) -
The inhibitory receptor LILRB4 (ILT3) modulates antigen presenting cell phenotype and, along with LILRB2 (ILT4), is upregulated in response to Salmonella infection
por: Brown, Damien P, et al.
Publicado: (2009) -
A target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma
por: Di Meo, Francesco, et al.
Publicado: (2023)